MilliporeSigma
All Photos(1)

S7771

Sigma-Aldrich

(S)-(−)-Sulpiride

≥98% (titration)

Synonym(s):
Levosulpiride, (S)-5-Aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide
Empirical Formula (Hill Notation):
C15H23N3O4S
CAS Number:
Molecular Weight:
341.43
MDL number:
PubChem Substance ID:
NACRES:
NA.77

Quality Level

assay

≥98% (titration)

mp

183-186 °C (lit.)

originator

Sanofi Aventis

storage temp.

2-8°C

SMILES string

CCN1CCC[C@H]1CNC(=O)c2cc(ccc2OC)S(N)(=O)=O

InChI

1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1

InChI key

BGRJTUBHPOOWDU-NSHDSACASA-N

Looking for similar products? Visit Product Comparison Guide

Application

(S)-(−)-Sulpiride was used to study the effect of dopamine D2 receptor function on activation of KCNQ potassium channels10 and on depression-like behavior in ovariectomized female rats.11

Packaging

5, 10 g in poly bottle

Biochem/physiol Actions

(S)-(−)-Sulpiride or Levosulpiride blocks the inhibitory enteric D2 receptors (neuronal and muscular). It has prokinetic activity and is effective in the treatment of functional dyspepsia and gastroparesis in insulin-dependent diabetes mellitus patients.7,8 Since dopamine controls human sexual function, (S)-(−)-Sulpiride is reportedly effective in treatment of erectile dysfunctions.9
D2 dopamine receptor antagonist; antipsychotic.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Enter Lot Number to search for Certificate of Analysis (COA).

Certificate of Origin

Enter Lot Number to search for Certificate of Origin (COO).

Takuya Hikima et al.
Cell reports, 35(1), 108951-108951 (2021-04-08)
Somatodendritic dopamine (DA) release from midbrain DA neurons activates D2 autoreceptors on these cells to regulate their activity. However, the source of autoregulatory DA remains controversial. Here, we test the hypothesis that D2 autoreceptors on a given DA neuron in
Jong Sam Baik et al.
Movement disorders : official journal of the Movement Disorder Society, 23(5), 746-748 (2008-01-11)
We describe three patients who presented with 4 to 5 Hz tremors of the suprahyoid region of the neck. Two developed their tremors in association with levosulpiride treatment. When they opened their mouths, the neck tremors disappeared; no tongue tremors
P Melga et al.
Diabetes care, 20(1), 55-58 (1997-01-01)
We evaluated the effect of chronic administration of levosulpiride, a prokinetic drug that is a selective antagonist for D2 dopamine receptors, on the glycemic control of IDDM subjects. The study was performed on 40 long-standing IDDM subjects with clinical signs
M Tonini et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 35(4), 244-250 (2003-06-13)
The dopamine D2 receptor antagonist levosulpiride is a substituted benzamide derivative, whose gastrokinetic properties are exploited clinically for the management of functional dyspepsia. However, for other benzamide derivatives, such as cisapride and mosapride, agonism towards serotonin 5-HT4 receptors is considered
W Hauber et al.
Behavioural brain research, 106(1-2), 143-150 (1999-12-14)
In the present study, the involvement of dopamine D1 and D2 receptors in the dorsal globus pallidus (GP) in motor control was investigated in rats. Results show that bilateral microinfusions of the dopamine D1 receptor antagonist SCH23390 or the dopamine

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service